Drug Discovery · Bedford, MA · Founded 2019 · Privately Held (backing)
Developer of neuroscience therapeutics designed to address mental health and central nervous system conditions. Delix Therapeutics is based in Bedford, MA and was founded in 2019. It was valued at $156 million at a grant in Jun 2024, the last priced event on record. It has raised $109 million across 1 recorded round; the latest was a $70 million Series A in Sep 2021.
PMV mark · valuation
$156.2M
Oct 2026
Priced at
a grant
Jun 2024
Total raised
$108.5M
Last round
Early Stage VC (Series A)
Sep 2021
No prints on record
No secondary trades in Delix Therapeutics shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Delix Therapeutics with a free account
·The complete investor list: 40 names
·Watch Delix Therapeutics: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Delix Therapeutics stock.
